Series C+ · 2026-10-19 · Healthcare
Nouscom raises $129.6M
72
AI Score
Amount
$129.6M
Round
Series C+
Lead
M Ventures, Revelation Partners
HQ
Basel, CH
Why it matters: The round's size and the FDA Fast Track designation for NOUS-209 show how cancer interception immunotherapy is moving toward registration trials.
Basel-based Nouscom closed an oversubscribed €120 million ($135 million) Series D co-led by M Ventures and Revelation Partners.
- Participants:
- Angelini Ventures, EIB, Neva SGR, 5AM Ventures, Andera Partners, Bpifrance, CDP Venture Capital, EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures, XGEN Ventures
- Source:
- EU-Startups Funding ↗ · Midu summary
Other rounds by Nouscom
Deal Dossier PRO
Pro feature
Deal Dossier for Nouscom
Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.
Generate dossier — ProFigures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).
Recent Healthcare rounds
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing